首页 > 最新文献

Frontiers in nuclear medicine (Lausanne, Switzerland)最新文献

英文 中文
PARALLELPROJ-an open-source framework for fast calculation of projections in tomography. PARALLELPROJ - 用于快速计算断层扫描投影的开源框架。
Pub Date : 2024-01-08 eCollection Date: 2023-01-01 DOI: 10.3389/fnume.2023.1324562
Georg Schramm, Kris Thielemans

In this article, we introduce parallelproj, a novel open-source framework designed for efficient parallel computation of projections in tomography leveraging either multiple CPU cores or GPUs. This framework efficiently implements forward and back projection functions for both sinogram and listmode data, utilizing Joseph's method, which is further extended to encompass time-of-flight (TOF) PET projections. Our evaluation involves a series of tests focusing on PET image reconstruction using data sourced from a state-of-the-art clinical PET/CT system. We thoroughly benchmark the performance of the projectors in non-TOF and TOF, sinogram, and listmode employing multi CPU-cores, hybrid CPU/GPU, and exclusive GPU mode. Moreover, we also investigate the timing of non-TOF sinogram projections calculated in STIR (Software for Tomographic Image Reconstruction) which recently integrated parallelproj as one of its projection backends. Our results indicate that the exclusive GPU mode provides acceleration factors between 25 and 68 relative to the multi-CPU-core mode. Furthermore, we demonstrate that OSEM listmode reconstruction of state-of-the-art real-world PET data sets is achievable within a few seconds using a single consumer GPU.

在本文中,我们将介绍一个新颖的开源框架--parallelproj,该框架旨在利用多个 CPU 内核或 GPU 高效并行计算断层摄影中的投影。该框架利用约瑟夫方法有效地实现了正弦图和列表模式数据的正向和反向投影功能,并进一步扩展到飞行时间(TOF)PET 投影。我们的评估包括一系列测试,重点是使用来自最先进的临床 PET/CT 系统的数据重建 PET 图像。我们采用多 CPU 核、CPU/GPU 混合模式和独占 GPU 模式,对投影仪在非 TOF 和 TOF、正弦图和列表模式下的性能进行了全面的基准测试。此外,我们还研究了在 STIR(断层图像重建软件)中计算的非 TOF 正弦曲线投影的时序,该软件最近集成了 parallelproj 作为其投影后端之一。我们的研究结果表明,相对于多 CPU 内核模式,独占 GPU 模式可提供 25 到 68 倍的加速度。此外,我们还证明了使用单个消费级 GPU 在几秒钟内就能完成最先进的真实 PET 数据集的 OSEM 列表模式重建。
{"title":"PARALLELPROJ-an open-source framework for fast calculation of projections in tomography.","authors":"Georg Schramm, Kris Thielemans","doi":"10.3389/fnume.2023.1324562","DOIUrl":"10.3389/fnume.2023.1324562","url":null,"abstract":"<p><p>In this article, we introduce parallelproj, a novel open-source framework designed for efficient parallel computation of projections in tomography leveraging either multiple CPU cores or GPUs. This framework efficiently implements forward and back projection functions for both sinogram and listmode data, utilizing Joseph's method, which is further extended to encompass time-of-flight (TOF) PET projections. Our evaluation involves a series of tests focusing on PET image reconstruction using data sourced from a state-of-the-art clinical PET/CT system. We thoroughly benchmark the performance of the projectors in non-TOF and TOF, sinogram, and listmode employing multi CPU-cores, hybrid CPU/GPU, and exclusive GPU mode. Moreover, we also investigate the timing of non-TOF sinogram projections calculated in STIR (Software for Tomographic Image Reconstruction) which recently integrated parallelproj as one of its projection backends. Our results indicate that the exclusive GPU mode provides acceleration factors between 25 and 68 relative to the multi-CPU-core mode. Furthermore, we demonstrate that OSEM listmode reconstruction of state-of-the-art real-world PET data sets is achievable within a few seconds using a single consumer GPU.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"3 ","pages":"1324562"},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data. 利用预先计算的单粒子轨迹标准 DNA 损伤数据,对放射性核素靶向治疗中的放射生物学效应进行逐个细胞的快速蒙特卡洛模拟。
Pub Date : 2023-12-06 eCollection Date: 2023-01-01 DOI: 10.3389/fnume.2023.1284558
A Lim, M Andriotty, T Yusufaly, G Agasthya, B Lee, C Wang

Introduction: We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.

Methods: The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a "pre-calculated" data library, constructed using the RTS code TOPAS-nBio, with "time stamps" manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published in vitro experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental in vitro system consisting of neuroendocrine tumor cells uniformly incubated with 177Lu.

Results and discussion: The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective "in silico clonogenic cell survival assay" for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.

简介:我们开发了一种新方法,可大幅加快放射生物学蒙特卡洛辐射轨迹结构(MC-RTS)计算的速度:我们开发了一种新方法,可大大加快逐个细胞的放射生物学蒙特卡洛辐射轨迹结构(MC-RTS)计算速度:该技术基于随机抽样和单粒子轨道(SPT)标准 DNA 损伤(SDD)文件的叠加,这些文件来自使用 RTS 代码 TOPAS-nBio 构建的 "预计算 "数据文件库,并人工添加了 "时间戳 "以纳入剂量率效应。这种带有时间戳的 SDD 文件随后可输入 MEDRAS,这是一种机理动力学模型,可计算各种辐射诱导的生物终点,如 DNA 双链断裂(DSB)、错误修复和染色体畸变以及细胞死亡。作为该方法的基准验证,我们计算了预测的随能量变化的DSB产量和DNA直接损伤与总损伤之比,两者均与已发表的体外实验数据一致。随后,我们应用该方法对神经内分泌肿瘤细胞均匀培养 177Lu 的体外实验系统进行了逐个细胞的超快速模拟:辐照后24小时和48小时的残余DSB结果与已发表的文献值一致。我们的工作证明了经济有效的 "硅学克隆细胞存活测定 "的可行性,可用于放射性药物和新型放射治疗方法的计算设计和开发。
{"title":"A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data.","authors":"A Lim, M Andriotty, T Yusufaly, G Agasthya, B Lee, C Wang","doi":"10.3389/fnume.2023.1284558","DOIUrl":"10.3389/fnume.2023.1284558","url":null,"abstract":"<p><strong>Introduction: </strong>We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.</p><p><strong>Methods: </strong>The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a \"pre-calculated\" data library, constructed using the RTS code TOPAS-nBio, with \"time stamps\" manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published <i>in vitro</i> experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental <i>in vitro</i> system consisting of neuroendocrine tumor cells uniformly incubated with <sup>177</sup>Lu.</p><p><strong>Results and discussion: </strong>The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective \"<i>in silico</i> clonogenic cell survival assay\" for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"3 ","pages":"1284558"},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Post-traumatic splenosis and potential pitfall for PSMA-PET. 病例报告:创伤后脾肿大和 PSMA-PET 的潜在隐患。
Pub Date : 2023-11-27 eCollection Date: 2023-01-01 DOI: 10.3389/fnume.2023.1319952
Marina Nearchou, Elizabeth Georgiou, Alexis Vrachimis, Konstantinos Ferentinos, Iosif Strouthos

Background: 18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.

Case presentation: A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT). PSMA-PET/CT revealed a histologically confirmed prostatic malignancy in the peripheral left zone. Unexpectedly, additional multiple highly PSMA-expressing intraabdominal formations were discovered. Based on apparent anatomic asplenia and a history of traumatic splenic rapture during childhood, a suspicion of post-traumatic splenosis was raised. For further non-invasive evaluation, a C-99 sulphur colloid scintigraphy with SPECT was conducted, confirming the presence of multiple functional ectopic splenic tissues. This is, to our best of knowledge, the first case utilising 18F-PSMA-1007-PET/CT and 99mTc-sulphur colloid SPECT to detect intraabdominal splenosis, highlighting the high potential of nuclear medicine in such trivial cases.

背景:18F-前列腺特异性膜抗原(PSMA)PET正迅速成为前列腺癌的金标准,既可用于中/高危患者的分期,也可用于生化检查失败患者的再分期。据我们所知,我们首次报告了一例可能被误诊为腹膜扩散的病例:一名 67 岁的高危前列腺癌患者接受了 18F-PSMA-1007 PET/CT (PSMA-PET/CT)分期检查。PSMA-PET/CT显示,经组织学证实的前列腺恶性肿瘤位于左侧外周区。意想不到的是,患者腹腔内还发现了多个高 PSMA 表达的肿瘤。基于明显的解剖学脾肿大和儿童时期的外伤性脾脏破裂病史,该患者被怀疑患有外伤后脾肿大。为了进行进一步的非侵入性评估,患者接受了 C-99 硫胶体闪烁扫描和 SPECT 检查,结果证实存在多个功能性异位脾组织。据我们所知,这是首例利用 18F-PSMA-1007-PET/CT 和 99mTc 硫胶体 SPECT 检测腹腔内脾脏病变的病例,凸显了核医学在此类琐碎病例中的巨大潜力。
{"title":"Case Report: Post-traumatic splenosis and potential pitfall for PSMA-PET.","authors":"Marina Nearchou, Elizabeth Georgiou, Alexis Vrachimis, Konstantinos Ferentinos, Iosif Strouthos","doi":"10.3389/fnume.2023.1319952","DOIUrl":"10.3389/fnume.2023.1319952","url":null,"abstract":"<p><strong>Background: </strong>18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.</p><p><strong>Case presentation: </strong>A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT). PSMA-PET/CT revealed a histologically confirmed prostatic malignancy in the peripheral left zone. Unexpectedly, additional multiple highly PSMA-expressing intraabdominal formations were discovered. Based on apparent anatomic asplenia and a history of traumatic splenic rapture during childhood, a suspicion of post-traumatic splenosis was raised. For further non-invasive evaluation, a C-99 sulphur colloid scintigraphy with SPECT was conducted, confirming the presence of multiple functional ectopic splenic tissues. This is, to our best of knowledge, the first case utilising 18F-PSMA-1007-PET/CT and 99mTc-sulphur colloid SPECT to detect intraabdominal splenosis, highlighting the high potential of nuclear medicine in such trivial cases.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"3 ","pages":"1319952"},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report 18F-FDG PET在TEMPI综合征中的首次应用:能否用于治疗评估?病例报告
Pub Date : 2023-10-26 DOI: 10.3389/fnume.2023.1273967
Henri Pasquesoone, Aurélien Callaud, Thibaut Carsuzaa, Thomas Chalopin, Maria-Joao Santiago-Ribeiro
TEMPI syndrome (TEMPI) compounds telangiectasias and polycythemia with elevated erythropoietin levels, monoclonal gammopathy, perirenal fluid collections, and intrapulmonary shunt. Although the pathophysiology of this syndrome remains unclarified, prior research has been established that it is a plasma cell neoplasm, often containing less than 10% bone marrow plasma cells. 18 F-FDG PET serves as a valuable instrument for initial staging and treatment monitoring in multiple myeloma management. Thus, 18 F-FDG PET can be legitimately applied for TEMPI assessment. Here, we present the first 18 F-FDG PET images for the initial evaluation and treatment monitoring of TEMPI in a 51-year-old woman, who exhibited polycythemia (EPO:5,448 mIU/ml) without JAK2 mutation, telangiectasias, monoclonal IgG lambda gammopathy (13.9) g/L and 7% dysmorphic plasma cells (CD38 + CD138+), occasionally clustered, in favor of tumoral plasmacytomas. The first PET scan exhibited hypermetabolic diffuse bone marrow, potentially related to polycythemia, accompanied by non-lytic bone hypermetabolic lesions in the femoral and humeral diaphysis, and ametabolic peri-renal fluid collections, brown fat, and pleural talcoma. Post-treatment 18 F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone) revealed a completely reduced signal of bone lesions, suggesting a complete response, which was substantiated both clinically and biologically, with the concurrent disappearance of telangiectasia and the monoclonal component, and the normalization of the EPO level. In future, additional data will be required to confirm the added value of 18 F-FDG PET with TEMPI. Nevertheless, 18 F-FDG PET can be a preferred tool for the extension workup and therapeutic evaluation of TEMPI syndrome.
TEMPI综合征(TEMPI)由毛细血管扩张和红细胞增多症合并促红细胞生成素水平升高、单克隆伽玛病、肾周积液和肺内分流引起。虽然该综合征的病理生理尚不清楚,但先前的研究已经确定它是一种浆细胞肿瘤,通常含有少于10%的骨髓浆细胞。18 F-FDG PET在多发性骨髓瘤的初始分期和治疗监测中具有重要作用。因此,18个F-FDG PET可以合法申请进行TEMPI评估。在这里,我们展示了一名51岁女性的第一次18张F-FDG PET图像,用于初步评估和治疗监测TEMPI,她表现为红细胞增多症(EPO:5,448 mIU/ml),无JAK2突变,毛细血管扩张,单克隆IgG λ γ病(13.9)g/L和7%畸形浆细胞(CD38 + CD138+),偶尔聚集,有利于肿瘤浆细胞瘤。第一次PET扫描显示高代谢性弥漫性骨髓,可能与红细胞增多症有关,伴股骨干和肱骨骨干非溶解性骨高代谢性病变,以及代谢性肾周积液、棕色脂肪和胸膜肉瘤。治疗后18 F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone)显示骨病变信号完全减少,表明完全缓解,这在临床和生物学上都得到证实,毛细血管扩张和单克隆成分同时消失,EPO水平正常化。未来,将需要额外的数据来确认18 F-FDG PET与TEMPI的附加值。尽管如此,18f - fdg PET可以作为temi综合征扩展检查和治疗评估的首选工具。
{"title":"First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report","authors":"Henri Pasquesoone, Aurélien Callaud, Thibaut Carsuzaa, Thomas Chalopin, Maria-Joao Santiago-Ribeiro","doi":"10.3389/fnume.2023.1273967","DOIUrl":"https://doi.org/10.3389/fnume.2023.1273967","url":null,"abstract":"TEMPI syndrome (TEMPI) compounds telangiectasias and polycythemia with elevated erythropoietin levels, monoclonal gammopathy, perirenal fluid collections, and intrapulmonary shunt. Although the pathophysiology of this syndrome remains unclarified, prior research has been established that it is a plasma cell neoplasm, often containing less than 10% bone marrow plasma cells. 18 F-FDG PET serves as a valuable instrument for initial staging and treatment monitoring in multiple myeloma management. Thus, 18 F-FDG PET can be legitimately applied for TEMPI assessment. Here, we present the first 18 F-FDG PET images for the initial evaluation and treatment monitoring of TEMPI in a 51-year-old woman, who exhibited polycythemia (EPO:5,448 mIU/ml) without JAK2 mutation, telangiectasias, monoclonal IgG lambda gammopathy (13.9) g/L and 7% dysmorphic plasma cells (CD38 + CD138+), occasionally clustered, in favor of tumoral plasmacytomas. The first PET scan exhibited hypermetabolic diffuse bone marrow, potentially related to polycythemia, accompanied by non-lytic bone hypermetabolic lesions in the femoral and humeral diaphysis, and ametabolic peri-renal fluid collections, brown fat, and pleural talcoma. Post-treatment 18 F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone) revealed a completely reduced signal of bone lesions, suggesting a complete response, which was substantiated both clinically and biologically, with the concurrent disappearance of telangiectasia and the monoclonal component, and the normalization of the EPO level. In future, additional data will be required to confirm the added value of 18 F-FDG PET with TEMPI. Nevertheless, 18 F-FDG PET can be a preferred tool for the extension workup and therapeutic evaluation of TEMPI syndrome.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134906255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging theragnostic radionuclide applications for hepatocellular carcinoma 新型放射性核素在肝细胞癌诊断中的应用
Pub Date : 2023-10-25 DOI: 10.3389/fnume.2023.1210982
N. E. Nyakale, C. Aldous, A. A. Gutta, X. Khuzwayo, L. Harry, M. M. Sathekge
Hepatocellular carcinoma (HCC) is a major global health problem. Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread. Theragnostic involves the use of molecular and genetic tests to identify specific biomarkers that can help guide treatment decisions and post treatment assess the dosimetry and localization of the treatment, thus assisting to guide future treatment. This can be done through either positron emission tomography (PET) scanning or single photon emission tomography (SPECT) using radiolabelled tracers that target specific molecules expressed by HCC cells or radioembolization. This technique can help identify the location and extent of the cancer, as well as provide information on the tumour's metabolic activity and blood supply. In summary, theragnostic is an emerging field that holds promise for improving the diagnosis and treatment of HCC. By combining diagnostic and therapeutic modalities into a single system, theragnostic can help guide personalized treatment decisions and improve patient outcomes.
肝细胞癌(HCC)是一个主要的全球健康问题。治疗是一个术语,指的是将诊断和治疗方式整合到一个个性化医疗的单一系统中。HCC的诊断包括使用影像学技术来诊断癌症并评估其特征,如大小、位置和扩散程度。治疗诊断包括使用分子和基因测试来识别特定的生物标志物,这些生物标志物可以帮助指导治疗决策,并在治疗后评估治疗的剂量和定位,从而帮助指导未来的治疗。这可以通过正电子发射断层扫描(PET)或单光子发射断层扫描(SPECT)来完成,使用放射性标记的示踪剂来靶向HCC细胞表达的特定分子或放射性栓塞。这项技术可以帮助确定癌症的位置和范围,并提供有关肿瘤代谢活动和血液供应的信息。总之,诊断是一个新兴的领域,有望改善HCC的诊断和治疗。通过将诊断和治疗方式结合到一个系统中,诊断可以帮助指导个性化的治疗决策并改善患者的预后。
{"title":"Emerging theragnostic radionuclide applications for hepatocellular carcinoma","authors":"N. E. Nyakale, C. Aldous, A. A. Gutta, X. Khuzwayo, L. Harry, M. M. Sathekge","doi":"10.3389/fnume.2023.1210982","DOIUrl":"https://doi.org/10.3389/fnume.2023.1210982","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a major global health problem. Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread. Theragnostic involves the use of molecular and genetic tests to identify specific biomarkers that can help guide treatment decisions and post treatment assess the dosimetry and localization of the treatment, thus assisting to guide future treatment. This can be done through either positron emission tomography (PET) scanning or single photon emission tomography (SPECT) using radiolabelled tracers that target specific molecules expressed by HCC cells or radioembolization. This technique can help identify the location and extent of the cancer, as well as provide information on the tumour's metabolic activity and blood supply. In summary, theragnostic is an emerging field that holds promise for improving the diagnosis and treatment of HCC. By combining diagnostic and therapeutic modalities into a single system, theragnostic can help guide personalized treatment decisions and improve patient outcomes.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135218429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiopharmaceutical administration practices—Are they best practice? 放射性药物管理规范-它们是最佳规范吗?
Pub Date : 2023-10-13 DOI: 10.3389/fnume.2023.1244660
Stephen Harris, James R. Crowley, Nancy Warden
Background The nuclear medicine community has stated that they are using best practices to gain venous access and administer radiopharmaceuticals, and therefore do not contribute to extravasations. We tested this hypothesis qualitatively and quantitatively by evaluating four different perspectives of current radiopharmaceutical administration practices: (1) clinical observations of nuclear medicine technologists on the job, (2) quality improvement (QI) projects, (3) a high-level survey of current practices in 10 acute care hospitals, (4) intravenous (IV) access site data for 29,343 procedures. These four areas were compared to the gold standard of pharmaceutical administration techniques. Results From clinical observations of radiopharmaceutical administrations in adult populations, technologists extensively used 24-gauge peripheral intravenous catheters (PIVCs) and butterfly needles. They also performed direct puncture (straight stick). Technologists predominantly chose veins in areas of flexion (hand, wrist, and antecubital fossa), rather than forearm vessels for IV access placement; in many circumstances, antecubital fossa vessels are chosen first, often without prior assessment for other suitable vessels. For selecting the injection vein, technologists sometimes used infrared vein finders but primarily performed blind sticks. Review of QI projects suggested that smaller gauge needles were contributing factors to extravasations. Additionally, the review of surveys from 10 hospitals revealed an absence of formalized protocols, training, knowledge, and skills necessary to ensure the safety/patency of IV devices prior to the administration of radiopharmaceuticals. Finally, findings from a review of IV access data for 29,343 procedures supported the observations described above. Conclusions We expect that nuclear medicine technologists have the best intentions when providing patient care, but many do not follow venous access best practices; they lack formal protocols, have not received the latest comprehensive training, and do not use the best placement tools and monitoring equipment. Thus, the presumption that most nuclear medicine technologists use best practices may not be accurate. In order to improve radiopharmaceutical administration and patient care, the nuclear medicine community should update technical standards to address the most recent peripheral IV access and administration best practices, provide technologists with vascular visualization tools and the proper training, develop and require annual vascular access competency, and provide active monitoring with center and patient-specific data to create ongoing feedback.
核医学界已经声明,他们正在使用最佳做法来获得静脉通路和管理放射性药物,因此不会导致外渗。我们通过评估当前放射性药物管理实践的四个不同视角,定性和定量地检验了这一假设:(1)在职核医学技术人员的临床观察,(2)质量改进(QI)项目,(3)对10家急症护理医院当前实践的高层调查,(4)29,343例手术的静脉注射(IV)访问现场数据。将这四个方面与药事管理技术的金标准进行了比较。结果从成人放射性药物给药的临床观察来看,技术人员广泛使用24号外周静脉导管(pivc)和蝴蝶针。他们还进行了直接穿刺(直棒)。技术人员主要选择屈曲部位的静脉(手、手腕和肘前窝),而不是前臂血管进行静脉注射;在许多情况下,首先选择肘前窝血管,通常没有事先评估其他合适的血管。为了选择注射静脉,技术人员有时使用红外静脉探测仪,但主要是盲棒。对QI项目的回顾表明,较小的针头是造成外渗的因素。此外,对10家医院调查的审查显示,在使用放射性药物之前,缺乏确保静脉注射装置安全/通畅所需的正式规程、培训、知识和技能。最后,对29343例静脉注射数据的回顾结果支持了上述观察结果。结论:我们期望核医学技术人员在提供患者护理时有最好的意图,但许多人没有遵循静脉通路的最佳做法;他们缺乏正式的协议,没有接受过最新的全面培训,也没有使用最好的安置工具和监测设备。因此,大多数核医学技术人员使用最佳实践的假设可能不准确。为了改善放射性药物管理和患者护理,核医学界应该更新技术标准,以解决最新的外周静脉注射和管理最佳实践,为技术人员提供血管可视化工具和适当的培训,发展和要求每年血管进入能力,并提供中心和患者特定数据的主动监测,以创建持续的反馈。
{"title":"Radiopharmaceutical administration practices—Are they best practice?","authors":"Stephen Harris, James R. Crowley, Nancy Warden","doi":"10.3389/fnume.2023.1244660","DOIUrl":"https://doi.org/10.3389/fnume.2023.1244660","url":null,"abstract":"Background The nuclear medicine community has stated that they are using best practices to gain venous access and administer radiopharmaceuticals, and therefore do not contribute to extravasations. We tested this hypothesis qualitatively and quantitatively by evaluating four different perspectives of current radiopharmaceutical administration practices: (1) clinical observations of nuclear medicine technologists on the job, (2) quality improvement (QI) projects, (3) a high-level survey of current practices in 10 acute care hospitals, (4) intravenous (IV) access site data for 29,343 procedures. These four areas were compared to the gold standard of pharmaceutical administration techniques. Results From clinical observations of radiopharmaceutical administrations in adult populations, technologists extensively used 24-gauge peripheral intravenous catheters (PIVCs) and butterfly needles. They also performed direct puncture (straight stick). Technologists predominantly chose veins in areas of flexion (hand, wrist, and antecubital fossa), rather than forearm vessels for IV access placement; in many circumstances, antecubital fossa vessels are chosen first, often without prior assessment for other suitable vessels. For selecting the injection vein, technologists sometimes used infrared vein finders but primarily performed blind sticks. Review of QI projects suggested that smaller gauge needles were contributing factors to extravasations. Additionally, the review of surveys from 10 hospitals revealed an absence of formalized protocols, training, knowledge, and skills necessary to ensure the safety/patency of IV devices prior to the administration of radiopharmaceuticals. Finally, findings from a review of IV access data for 29,343 procedures supported the observations described above. Conclusions We expect that nuclear medicine technologists have the best intentions when providing patient care, but many do not follow venous access best practices; they lack formal protocols, have not received the latest comprehensive training, and do not use the best placement tools and monitoring equipment. Thus, the presumption that most nuclear medicine technologists use best practices may not be accurate. In order to improve radiopharmaceutical administration and patient care, the nuclear medicine community should update technical standards to address the most recent peripheral IV access and administration best practices, provide technologists with vascular visualization tools and the proper training, develop and require annual vascular access competency, and provide active monitoring with center and patient-specific data to create ongoing feedback.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135854885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mini review of first-in-human integrin αvβ6 PET tracers 首次人用整合素αvβ6 PET示踪剂的综述
Pub Date : 2023-10-09 DOI: 10.3389/fnume.2023.1271208
Richard H. Kimura, Andrei Iagaru, H. Henry Guo
This mini review of clinically-evaluated integrin αvβ6 PET-tracers reveals distinct differences in human-biodistribution patterns between linear peptides, including disulfide-stabilized formats, compared to head-to-tail cyclized peptides. All PET tracers mentioned in this mini review were able to delineate disease from normal tissues, but some αvβ6 PET tracers are better than others for particular clinical applications. Each αvβ6 PET tracer was validated for its ability to bind integrin αvβ6 with high affinity. However, all the head-to-tail cyclized peptide PET-tracers reviewed here did not accumulate in the GI-tract, in striking contrast to the linear and disulfide-bonded counterparts currently undergoing clinical evaluation in cancer, IPF and long COVID. Multiple independent investigators have reported the presence of β6 mRNA as well as αvβ6 protein in the GI-tract. Currently, there remains further need for biochemical, clinical, and structural data to satisfactorily explain the state-of-the-art in human αvβ6-imaging.
这项对临床评估的整合素αvβ6 pet示踪剂的小型综述揭示了线性肽(包括二硫稳定格式)与从头到尾环化肽在人体生物分布模式上的明显差异。在这篇小型综述中提到的所有PET示踪剂都能够从正常组织中描绘疾病,但在特定的临床应用中,一些αvβ6 PET示踪剂比其他示踪剂更好。每个αvβ6 PET示踪剂都具有高亲和力结合整合素αvβ6的能力。然而,本文综述的所有首尾环化肽pet示踪剂均未在胃肠道中积累,这与目前正在癌症、IPF和长COVID中进行临床评估的线性和二硫键化示踪剂形成鲜明对比。多个独立研究人员报道了gi道中β6 mRNA和αvβ6蛋白的存在。目前,仍需要进一步的生化、临床和结构数据来令人满意地解释人类αvβ6成像的最新进展。
{"title":"Mini review of first-in-human integrin αvβ6 PET tracers","authors":"Richard H. Kimura, Andrei Iagaru, H. Henry Guo","doi":"10.3389/fnume.2023.1271208","DOIUrl":"https://doi.org/10.3389/fnume.2023.1271208","url":null,"abstract":"This mini review of clinically-evaluated integrin αvβ6 PET-tracers reveals distinct differences in human-biodistribution patterns between linear peptides, including disulfide-stabilized formats, compared to head-to-tail cyclized peptides. All PET tracers mentioned in this mini review were able to delineate disease from normal tissues, but some αvβ6 PET tracers are better than others for particular clinical applications. Each αvβ6 PET tracer was validated for its ability to bind integrin αvβ6 with high affinity. However, all the head-to-tail cyclized peptide PET-tracers reviewed here did not accumulate in the GI-tract, in striking contrast to the linear and disulfide-bonded counterparts currently undergoing clinical evaluation in cancer, IPF and long COVID. Multiple independent investigators have reported the presence of β6 mRNA as well as αvβ6 protein in the GI-tract. Currently, there remains further need for biochemical, clinical, and structural data to satisfactorily explain the state-of-the-art in human αvβ6-imaging.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135095187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[18F]NaF PET/CT imaging of response to single fraction SABR to bone metastases from breast cancer [18F]单组分SABR对乳腺癌骨转移的影响
Pub Date : 2023-10-04 DOI: 10.3389/fnume.2023.1197397
Nicholas Hardcastle, Yang Liu, Shankar Siva, Steven David
Breast cancer commonly metastasises to the skeleton, and stereotactic ablative body radiation therapy (SABR) is an emerging treatment for oligometastatic disease. Accurately imaging bone metastases and their response to treatment is challenging. [ 18 F]NaF-PET has a higher sensitivity and specificity than conventional bone scans for detecting breast cancer bone metastases. In this pre-defined secondary analysis of a prospective trial, we evaluated the change in [ 18 F]NaF uptake after SABR. Patients with oligometastatic breast cancer received a single fraction of 20 Gy to up to three bone metastases. [ 18 F]NaF-PET was acquired before and 12 months after SABR. Pre- and post-treatment [ 18 F]NaF-PET images were registered to the treatment planning CT. The relative change in tumour SUV max and SUV mean was quantified. The intersection of each of the radiation therapy isodose contours with a non-tumour bone was created. The change in SUV mean in sub-volumes of non-tumour bone receiving doses of 0–20 Gy was quantified. In total, 14 patients, with 17 bone metastases, were available for analysis. A total of 15 metastases exhibited a reduction in SUV max ; the median reduction was 42% and the maximum reduction 82%. An increased absolute reduction in SUV max was observed with higher pre-treatment SUV max . One patient exhibited increased SUV max after treatment, which was attributed to normal peri-tumoural bone regeneration in the context of a bone metastasis. There was a median reduction of 15%–34% for non-tumour bone in each dose level.
乳腺癌通常转移到骨骼,立体定向消融体放射治疗(SABR)是一种新兴的治疗低转移性疾病的方法。准确成像骨转移及其对治疗的反应是具有挑战性的。[18 F] nafe - pet在检测乳腺癌骨转移方面比传统骨扫描具有更高的敏感性和特异性。在这项预先定义的前瞻性试验的二次分析中,我们评估了SABR后[18 F]NaF摄取的变化。少转移性乳腺癌患者接受20 Gy的单次放疗,最多可达到三个骨转移灶。[18 F]在SABR前和SABR后12个月获得NaF-PET。将治疗前和治疗后[18 F]的NaF-PET图像注册到治疗计划CT上。量化肿瘤SUV max和SUV mean的相对变化。每个放射治疗等剂量等值线与非肿瘤骨的交点被创建。对接受0-20 Gy剂量的非肿瘤骨亚体积中SUV平均值的变化进行了量化。共有14例患者,17例骨转移,可用于分析。共有15例转移灶的SUV max降低;中位降幅为42%,最大降幅为82%。SUV max的绝对减少量随着预处理SUV max的增加而增加。一名患者在治疗后表现出增加的SUV max,这归因于骨转移背景下正常的肿瘤周围骨再生。在每个剂量水平下,非肿瘤骨的中位数减少15%-34%。
{"title":"[18F]NaF PET/CT imaging of response to single fraction SABR to bone metastases from breast cancer","authors":"Nicholas Hardcastle, Yang Liu, Shankar Siva, Steven David","doi":"10.3389/fnume.2023.1197397","DOIUrl":"https://doi.org/10.3389/fnume.2023.1197397","url":null,"abstract":"Breast cancer commonly metastasises to the skeleton, and stereotactic ablative body radiation therapy (SABR) is an emerging treatment for oligometastatic disease. Accurately imaging bone metastases and their response to treatment is challenging. [ 18 F]NaF-PET has a higher sensitivity and specificity than conventional bone scans for detecting breast cancer bone metastases. In this pre-defined secondary analysis of a prospective trial, we evaluated the change in [ 18 F]NaF uptake after SABR. Patients with oligometastatic breast cancer received a single fraction of 20 Gy to up to three bone metastases. [ 18 F]NaF-PET was acquired before and 12 months after SABR. Pre- and post-treatment [ 18 F]NaF-PET images were registered to the treatment planning CT. The relative change in tumour SUV max and SUV mean was quantified. The intersection of each of the radiation therapy isodose contours with a non-tumour bone was created. The change in SUV mean in sub-volumes of non-tumour bone receiving doses of 0–20 Gy was quantified. In total, 14 patients, with 17 bone metastases, were available for analysis. A total of 15 metastases exhibited a reduction in SUV max ; the median reduction was 42% and the maximum reduction 82%. An increased absolute reduction in SUV max was observed with higher pre-treatment SUV max . One patient exhibited increased SUV max after treatment, which was attributed to normal peri-tumoural bone regeneration in the context of a bone metastasis. There was a median reduction of 15%–34% for non-tumour bone in each dose level.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"232 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135591625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of deep space exploration risks and mitigations against radiation and microgravity 评估深空探测风险及对辐射和微重力的缓解措施
Pub Date : 2023-09-21 DOI: 10.3389/fnume.2023.1225034
William Dobney, Louise Mols, Dhruti Mistry, Kevin Tabury, Bjorn Baselet, Sarah Baatout
Ionizing radiation and microgravity are two considerable health risks encountered during deep space exploration. Both have deleterious effects on the human body. On one hand, weightlessness is known to induce a weakening of the immune system, a delayed wound healing and musculoskeletal, cardiovascular, and sensorimotor deconditioning. On the other hand, radiation exposure can lead to long-term health effects such as cancer and cataract, as well as adverse effects to the central nervous and cardiovascular systems. Ionizing radiation originates from three main sources in space: galactic cosmic radiation, solar particle events and solar winds. Furthermore, inside the spacecraft and inside certain space habitats on Lunar and Martian surfaces, the crew is exposed to intravehicular radiation, which arises from nuclear reactions between space radiation and matter. Besides the approaches already in use, such as radiation shielding materials (such as aluminium, water or polyethylene), alternative shielding materials (including boron nanotubes, complex hybrids, composite hybrid materials, and regolith) and active shielding (using fields to deflect radiation particles) are being investigated for their abilities to mitigate the effects of ionizing radiation. From a biological point-of-view, it can be predicted that exposure to ionizing radiation during missions beyond Low Earth Orbit (LEO) will affect the human body in undesirable ways, e.g., increasing the risks of cataract, cardiovascular and central nervous system diseases, carcinogenesis, as well as accelerated ageing. Therefore, it is necessary to assess the risks related to deep space exploration and to develop mitigation strategies to reduce these risks to a tolerable level. By using biomarkers for radiation sensitivity, space agencies are developing extensive personalised medical examination programmes to determine an astronaut's vulnerability to radiation. Moreover, researchers are developing pharmacological solutions (e.g., radioprotectors and radiomitigators) to proactively or reactively protect astronauts during deep space exploration. Finally, research is necessary to develop more effective countermeasures for use in future human space missions, which can also lead to improvements to medical care on Earth. This review will discuss the risks space travel beyond LEO poses to astronauts, methods to monitor astronauts' health, and possible approaches to mitigate these risks.
电离辐射和微重力是深空探测过程中遇到的两大健康风险。两者都对人体有害。一方面,已知失重会导致免疫系统减弱,伤口愈合延迟,肌肉骨骼、心血管和感觉运动失调。另一方面,辐射暴露会导致长期的健康影响,如癌症和白内障,以及对中枢神经和心血管系统的不利影响。电离辐射在太空中有三个主要来源:银河宇宙辐射、太阳粒子事件和太阳风。此外,在航天器内以及月球和火星表面的某些太空栖息地内,机组人员暴露在由空间辐射与物质之间的核反应产生的舱内辐射中。除了已经使用的方法,如辐射屏蔽材料(如铝、水或聚乙烯),替代屏蔽材料(包括硼纳米管、复杂杂化材料、复合杂化材料和风化层)和主动屏蔽(利用场偏转辐射粒子)正在研究它们减轻电离辐射影响的能力。从生物学的角度来看,可以预测,在低地球轨道(LEO)以外的任务期间暴露于电离辐射将以不希望的方式影响人体,例如,增加白内障、心血管和中枢神经系统疾病、致癌以及加速衰老的风险。因此,有必要评估与深空探索有关的风险,并制定缓解战略,将这些风险降低到可容忍的水平。通过使用辐射敏感性的生物标志物,各空间机构正在制定广泛的个性化医疗检查方案,以确定宇航员对辐射的脆弱性。此外,研究人员正在开发药理学解决方案(例如,辐射保护剂和辐射缓释剂),以便在深空探索期间主动或被动地保护宇航员。最后,有必要进行研究,以制定更有效的对策,用于未来的人类空间任务,这也可以改善地球上的医疗保健。本综述将讨论近地轨道以外的太空旅行对宇航员构成的风险、监测宇航员健康的方法以及减轻这些风险的可能途径。
{"title":"Evaluation of deep space exploration risks and mitigations against radiation and microgravity","authors":"William Dobney, Louise Mols, Dhruti Mistry, Kevin Tabury, Bjorn Baselet, Sarah Baatout","doi":"10.3389/fnume.2023.1225034","DOIUrl":"https://doi.org/10.3389/fnume.2023.1225034","url":null,"abstract":"Ionizing radiation and microgravity are two considerable health risks encountered during deep space exploration. Both have deleterious effects on the human body. On one hand, weightlessness is known to induce a weakening of the immune system, a delayed wound healing and musculoskeletal, cardiovascular, and sensorimotor deconditioning. On the other hand, radiation exposure can lead to long-term health effects such as cancer and cataract, as well as adverse effects to the central nervous and cardiovascular systems. Ionizing radiation originates from three main sources in space: galactic cosmic radiation, solar particle events and solar winds. Furthermore, inside the spacecraft and inside certain space habitats on Lunar and Martian surfaces, the crew is exposed to intravehicular radiation, which arises from nuclear reactions between space radiation and matter. Besides the approaches already in use, such as radiation shielding materials (such as aluminium, water or polyethylene), alternative shielding materials (including boron nanotubes, complex hybrids, composite hybrid materials, and regolith) and active shielding (using fields to deflect radiation particles) are being investigated for their abilities to mitigate the effects of ionizing radiation. From a biological point-of-view, it can be predicted that exposure to ionizing radiation during missions beyond Low Earth Orbit (LEO) will affect the human body in undesirable ways, e.g., increasing the risks of cataract, cardiovascular and central nervous system diseases, carcinogenesis, as well as accelerated ageing. Therefore, it is necessary to assess the risks related to deep space exploration and to develop mitigation strategies to reduce these risks to a tolerable level. By using biomarkers for radiation sensitivity, space agencies are developing extensive personalised medical examination programmes to determine an astronaut's vulnerability to radiation. Moreover, researchers are developing pharmacological solutions (e.g., radioprotectors and radiomitigators) to proactively or reactively protect astronauts during deep space exploration. Finally, research is necessary to develop more effective countermeasures for use in future human space missions, which can also lead to improvements to medical care on Earth. This review will discuss the risks space travel beyond LEO poses to astronauts, methods to monitor astronauts' health, and possible approaches to mitigate these risks.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136130261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiolabeled iron oxide nanoparticles functionalized with PSMA/BN ligands for dual-targeting of prostate cancer PSMA/BN配体功能化的放射性标记氧化铁纳米颗粒用于前列腺癌的双靶向治疗
Pub Date : 2023-09-20 DOI: 10.3389/fnume.2023.1184309
Danae Efremia Bajwa, Evangelia-Alexandra Salvanou, Maria Theodosiou, Theodora S. Koutsikou, Eleni K. Efthimiadou, Penelope Bouziotis, Christos Liolios
Introduction Prostate cancer (PCa) is the second most frequent cancer diagnosis in men and the fifth leading cause of death worldwide. Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) receptors are overexpressed in PCa. In this study, we have developed iron oxide nanoparticles (IONs) functionalized with the Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) ligands for dual targeting of Prostate cancer. Methods IONs were developed with a thin silica layer on their surface with MPTES (carrying -SH groups, IONs-SH), and they were coupled either with a pharmacophore targeting PSMA (IONs-PSMA) or with bombesin peptide (IONs-BN), targeting GRP receptors, or with both (IONs-PSMA/BN). The functionalized IONs were characterized for their size, zeta potential, and efficiency of functionalization using dynamic light scattering (DLS) and Fourier-Transform Infrared Spectroscopy (FT-IR). All the aforementioned types of IONs were radiolabeled directly with Technetium-99m ( 99m Tc) and evaluated for their radiolabeling efficiency, stability, and binding ability on two different PCa cell lines (PC3 and LNCaP). Results and Discussion The MTT assay demonstrated low toxicity of the IONs against PC3 and LNCaP cells, while the performed wound-healing assay further proved that these nanostructures did not affect cellular growth mechanisms. The observed hemolysis ratio after co-incubation with red blood cells was extremely low. Furthermore, the 99m Tc-radiolabeled IONs showed good stability in human serum, DTPA, and histidine, and high specific binding rates in cancer cells, supporting their future utilization as potential diagnostic tools for PCa with Single Photon Emission Computed Tomography (SPECT) imaging.
前列腺癌(PCa)是男性第二大最常见的癌症诊断,也是全球第五大死亡原因。前列腺特异性膜抗原(PSMA)和胃泌素释放肽(GRP)受体在前列腺癌中过表达。在这项研究中,我们开发了具有前列腺特异性膜抗原(PSMA)和胃泌素释放肽(GRP)配体功能化的氧化铁纳米颗粒(离子),用于前列腺癌的双重靶向治疗。方法将离子与MPTES(携带-SH基团,IONs-SH)表面形成一层薄薄的二氧化硅层,并与靶向PSMA的药效团(IONs-PSMA)或靶向GRP受体的bombesin肽(IONs-BN)偶联,或同时与两者(IONs-PSMA/BN)偶联。利用动态光散射(DLS)和傅里叶变换红外光谱(FT-IR)对功能化离子的大小、ζ电位和功能化效率进行了表征。用锝-99m (99m Tc)直接对上述所有类型的离子进行放射性标记,并在两种不同的PCa细胞系(PC3和LNCaP)上评估其放射性标记效率、稳定性和结合能力。MTT实验证明了离子对PC3和LNCaP细胞的低毒性,而进行的伤口愈合实验进一步证明了这些纳米结构不影响细胞生长机制。与红细胞共孵育后观察到溶血率极低。此外,99m tc放射性标记离子在人血清、DTPA和组氨酸中表现出良好的稳定性,在癌细胞中具有很高的特异性结合率,支持它们未来作为单光子发射计算机断层扫描(SPECT)诊断前列腺癌的潜在工具。
{"title":"Radiolabeled iron oxide nanoparticles functionalized with PSMA/BN ligands for dual-targeting of prostate cancer","authors":"Danae Efremia Bajwa, Evangelia-Alexandra Salvanou, Maria Theodosiou, Theodora S. Koutsikou, Eleni K. Efthimiadou, Penelope Bouziotis, Christos Liolios","doi":"10.3389/fnume.2023.1184309","DOIUrl":"https://doi.org/10.3389/fnume.2023.1184309","url":null,"abstract":"Introduction Prostate cancer (PCa) is the second most frequent cancer diagnosis in men and the fifth leading cause of death worldwide. Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) receptors are overexpressed in PCa. In this study, we have developed iron oxide nanoparticles (IONs) functionalized with the Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) ligands for dual targeting of Prostate cancer. Methods IONs were developed with a thin silica layer on their surface with MPTES (carrying -SH groups, IONs-SH), and they were coupled either with a pharmacophore targeting PSMA (IONs-PSMA) or with bombesin peptide (IONs-BN), targeting GRP receptors, or with both (IONs-PSMA/BN). The functionalized IONs were characterized for their size, zeta potential, and efficiency of functionalization using dynamic light scattering (DLS) and Fourier-Transform Infrared Spectroscopy (FT-IR). All the aforementioned types of IONs were radiolabeled directly with Technetium-99m ( 99m Tc) and evaluated for their radiolabeling efficiency, stability, and binding ability on two different PCa cell lines (PC3 and LNCaP). Results and Discussion The MTT assay demonstrated low toxicity of the IONs against PC3 and LNCaP cells, while the performed wound-healing assay further proved that these nanostructures did not affect cellular growth mechanisms. The observed hemolysis ratio after co-incubation with red blood cells was extremely low. Furthermore, the 99m Tc-radiolabeled IONs showed good stability in human serum, DTPA, and histidine, and high specific binding rates in cancer cells, supporting their future utilization as potential diagnostic tools for PCa with Single Photon Emission Computed Tomography (SPECT) imaging.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136314063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in nuclear medicine (Lausanne, Switzerland)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1